Fate Therapeutics (FATE) Tops Q3 EPS by 10c

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.46), $0.10 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $1.94 million versus the consensus estimate of $1.59 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Apple’s big price hike seen as "an unprecedented push to protect margins"
• Johnson & Johnson (JNJ) PT Raised to $270 at Guggenheim